Atossa Therapeutics Inc.
05/08/2026 | Press release | Distributed by Public on 05/08/2026 06:00
Proxy Results (Form 8-K)
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 7, 2026, Atossa Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on March 19, 2026, the record date for the Annual Meeting, there were 8,611,361 shares of common stock, par value $0.18 per share (the "Common Stock"), entitled to vote at the meeting.
At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below.
(i)
Election of Directors
The stockholders elected the three Class II directors by the following votes:
|
Nominee |
Votes |
Votes |
Broker Non-Votes |
|
•
Stephen J. Galli, M.D.
|
1,726,410 |
288,389 |
2,222,160 |
|
•
Richard I. Steinhart
|
1,730,171 |
284,628 |
2,222,160 |
|
•
Tessa Cigler, M.D., M.P.H.
|
1,750,694 |
264,105 |
2,222,160 |
(ii)
Ratification of Independent Auditor
The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:
|
Votes |
Votes |
Abstentions |
Broker Non-Votes |
|
3,714,889 |
370,496 |
151,574 |
0 |
(iii)
Approval of Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split of the Common Stock, if Deemed Necessary or Appropriate by the Board
The stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive, if determined necessary or appropriate by the Board, by the following votes:
|
Votes |
Votes |
Abstentions |
Broker Non-Votes |
|
2,336,815 |
1,866,873 |
33,271 |
0 |
(iv)
Advisory Vote on Executive Compensation
The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers by the following votes:
|
Votes |
Votes |
Abstentions |
Broker Non-Votes |
|
1,530,390 |
444,616 |
39,793 |
2,222,160 |
* * *
Atossa Therapeutics Inc. published this content on May 08, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 08, 2026 at 12:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]